Loading...
•
Sep 30
QIAGEN Q3 2025 Earnings Report
QIAGEN exceeded expectations in Q3 2025, reporting strong sales growth and profitability while raising its full-year adjusted EPS guidance.
Key Takeaways
QIAGEN delivered solid Q3 2025 results with $533 million in revenue and $0.61 adjusted EPS, surpassing its guidance. Growth was driven by QIAstat-Dx, QuantiFERON, and Sample technologies. The company raised its full-year adjusted EPS target and reaffirmed its revenue growth outlook.
Reported net sales of $533 million in Q3 2025, up 6% year-over-year at actual rates.
Adjusted diluted EPS was $0.61, exceeding the previous outlook.
Achieved a strong adjusted operating income margin of 29.6%.
Announced the acquisition of Parse Biosciences to expand into the single-cell market.
QIAGEN
QIAGEN
Forward Guidance
QIAGEN reaffirmed full-year 2025 net sales growth of about 4-5% CER and raised its adjusted EPS target to approximately $2.38 CER.
Positive Outlook
- Raised full-year adjusted EPS guidance to ~$2.38 CER from ~$2.35 CER
- Reaffirmed 2025 net sales growth target of 4-5% CER
- Expected 2025 adjusted operating margin of ~29.5% despite headwinds
- Parse Biosciences acquisition expands portfolio into fast-growing single-cell market
- $500 million share repurchase to be completed in January 2026
Challenges Ahead
- Macroeconomic headwinds including currency fluctuations and tariffs
- CEO transition introduces potential leadership uncertainty
- Integration risk from Parse Biosciences acquisition
- Adjusted margins are impacted by external cost pressures
- Maintaining leverage target amid capital returns and acquisitions may be challenging